Report cover image

Peptide CDMO Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 131 Pages
SKU # APRC20351877

Description

Summary

According to APO Research, The global Peptide CDMO market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Peptide CDMO include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO.
The Peptide CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Peptide CDMO Segment by Company

Xinbang Pharma
ScinoPharm
SN Biopharm
Genscript
AmbioPharm
USV Peptides
Thermofischer
PolyPeptide
Piramal Pharma
JPT
CPC Scientific
CordenPharma
CBL
Bio Basic
Bachem
Peptide CDMO Segment by Type

APIs and Intermediates
FDF
Peptide CDMO Segment by Application

Commercial
Academic Research
Other
Peptide CDMO Segment by Application

Commercial
Academic Research
Other
Peptide CDMO Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Peptide CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

131 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Peptide CDMO by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 APIs and Intermediates
2.2.3 FDF
2.3 Peptide CDMO by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Commercial
2.3.3 Academic Research
2.3.4 Other
2.4 Assumptions and Limitations
3 Peptide CDMO Breakdown Data by Type
3.1 Global Peptide CDMO Historic Market Size by Type (2020-2025)
3.2 Global Peptide CDMO Forecasted Market Size by Type (2026-2031)
4 Peptide CDMO Breakdown Data by Application
4.1 Global Peptide CDMO Historic Market Size by Application (2020-2025)
4.2 Global Peptide CDMO Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Peptide CDMO Market Perspective (2020-2031)
5.2 Global Peptide CDMO Growth Trends by Region
5.2.1 Global Peptide CDMO Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Peptide CDMO Historic Market Size by Region (2020-2025)
5.2.3 Peptide CDMO Forecasted Market Size by Region (2026-2031)
5.3 Peptide CDMO Market Dynamics
5.3.1 Peptide CDMO Industry Trends
5.3.2 Peptide CDMO Market Drivers
5.3.3 Peptide CDMO Market Challenges
5.3.4 Peptide CDMO Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Peptide CDMO Players by Revenue
6.1.1 Global Top Peptide CDMO Players by Revenue (2020-2025)
6.1.2 Global Peptide CDMO Revenue Market Share by Players (2020-2025)
6.2 Global Peptide CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Peptide CDMO Head Office and Area Served
6.4 Global Peptide CDMO Players, Product Type & Application
6.5 Global Peptide CDMO Manufacturers Established Date
6.6 Global Peptide CDMO Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Peptide CDMO Market Size (2020-2031)
7.2 North America Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Peptide CDMO Market Size by Country (2020-2025)
7.4 North America Peptide CDMO Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Peptide CDMO Market Size (2020-2031)
8.2 Europe Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Peptide CDMO Market Size by Country (2020-2025)
8.4 Europe Peptide CDMO Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Peptide CDMO Market Size (2020-2031)
9.2 Asia-Pacific Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Peptide CDMO Market Size by Country (2020-2025)
9.4 Asia-Pacific Peptide CDMO Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Peptide CDMO Market Size (2020-2031)
10.2 South America Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Peptide CDMO Market Size by Country (2020-2025)
10.4 South America Peptide CDMO Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Peptide CDMO Market Size (2020-2031)
11.2 Middle East & Africa Peptide CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Peptide CDMO Market Size by Country (2020-2025)
11.4 Middle East & Africa Peptide CDMO Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Xinbang Pharma
12.1.1 Xinbang Pharma Company Information
12.1.2 Xinbang Pharma Business Overview
12.1.3 Xinbang Pharma Revenue in Peptide CDMO Business (2020-2025)
12.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
12.1.5 Xinbang Pharma Recent Developments
12.2 ScinoPharm
12.2.1 ScinoPharm Company Information
12.2.2 ScinoPharm Business Overview
12.2.3 ScinoPharm Revenue in Peptide CDMO Business (2020-2025)
12.2.4 ScinoPharm Peptide CDMO Product Portfolio
12.2.5 ScinoPharm Recent Developments
12.3 SN Biopharm
12.3.1 SN Biopharm Company Information
12.3.2 SN Biopharm Business Overview
12.3.3 SN Biopharm Revenue in Peptide CDMO Business (2020-2025)
12.3.4 SN Biopharm Peptide CDMO Product Portfolio
12.3.5 SN Biopharm Recent Developments
12.4 Genscript
12.4.1 Genscript Company Information
12.4.2 Genscript Business Overview
12.4.3 Genscript Revenue in Peptide CDMO Business (2020-2025)
12.4.4 Genscript Peptide CDMO Product Portfolio
12.4.5 Genscript Recent Developments
12.5 AmbioPharm
12.5.1 AmbioPharm Company Information
12.5.2 AmbioPharm Business Overview
12.5.3 AmbioPharm Revenue in Peptide CDMO Business (2020-2025)
12.5.4 AmbioPharm Peptide CDMO Product Portfolio
12.5.5 AmbioPharm Recent Developments
12.6 USV Peptides
12.6.1 USV Peptides Company Information
12.6.2 USV Peptides Business Overview
12.6.3 USV Peptides Revenue in Peptide CDMO Business (2020-2025)
12.6.4 USV Peptides Peptide CDMO Product Portfolio
12.6.5 USV Peptides Recent Developments
12.7 Thermofischer
12.7.1 Thermofischer Company Information
12.7.2 Thermofischer Business Overview
12.7.3 Thermofischer Revenue in Peptide CDMO Business (2020-2025)
12.7.4 Thermofischer Peptide CDMO Product Portfolio
12.7.5 Thermofischer Recent Developments
12.8 PolyPeptide
12.8.1 PolyPeptide Company Information
12.8.2 PolyPeptide Business Overview
12.8.3 PolyPeptide Revenue in Peptide CDMO Business (2020-2025)
12.8.4 PolyPeptide Peptide CDMO Product Portfolio
12.8.5 PolyPeptide Recent Developments
12.9 Piramal Pharma
12.9.1 Piramal Pharma Company Information
12.9.2 Piramal Pharma Business Overview
12.9.3 Piramal Pharma Revenue in Peptide CDMO Business (2020-2025)
12.9.4 Piramal Pharma Peptide CDMO Product Portfolio
12.9.5 Piramal Pharma Recent Developments
12.10 JPT
12.10.1 JPT Company Information
12.10.2 JPT Business Overview
12.10.3 JPT Revenue in Peptide CDMO Business (2020-2025)
12.10.4 JPT Peptide CDMO Product Portfolio
12.10.5 JPT Recent Developments
12.11 CPC Scientific
12.11.1 CPC Scientific Company Information
12.11.2 CPC Scientific Business Overview
12.11.3 CPC Scientific Revenue in Peptide CDMO Business (2020-2025)
12.11.4 CPC Scientific Peptide CDMO Product Portfolio
12.11.5 CPC Scientific Recent Developments
12.12 CordenPharma
12.12.1 CordenPharma Company Information
12.12.2 CordenPharma Business Overview
12.12.3 CordenPharma Revenue in Peptide CDMO Business (2020-2025)
12.12.4 CordenPharma Peptide CDMO Product Portfolio
12.12.5 CordenPharma Recent Developments
12.13 CBL
12.13.1 CBL Company Information
12.13.2 CBL Business Overview
12.13.3 CBL Revenue in Peptide CDMO Business (2020-2025)
12.13.4 CBL Peptide CDMO Product Portfolio
12.13.5 CBL Recent Developments
12.14 Bio Basic
12.14.1 Bio Basic Company Information
12.14.2 Bio Basic Business Overview
12.14.3 Bio Basic Revenue in Peptide CDMO Business (2020-2025)
12.14.4 Bio Basic Peptide CDMO Product Portfolio
12.14.5 Bio Basic Recent Developments
12.15 Bachem
12.15.1 Bachem Company Information
12.15.2 Bachem Business Overview
12.15.3 Bachem Revenue in Peptide CDMO Business (2020-2025)
12.15.4 Bachem Peptide CDMO Product Portfolio
12.15.5 Bachem Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.